The global Pain Therapeutic Injectables Market holds a valuation of USD 19.3 Billion in 2023, and it is further projected to expand at a CAGR of 4.5% over the forecasted years. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2023 | USD 19.3 Billion |
| Market Value 2033 | USD 30.9 Billion |
| CAGR 2023 to 2033 | 4.5% |
| Market Share of Top 5 Countries | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Therapeutic injections for treating pain can aid in reducing swelling and discomfort. Depending on the location, muscle injury, skeletal or neurological structures, and overall symptoms, there are choices for injectable treatment for almost any sort of pain a patient is experiencing.
These injections can be administered intravenously, subcutaneously, or through an epidural catheter. These injectables are frequently used to treat acute pain which occurs because of injuries, post-operative pain, or chronic pain due to any kind of illness.
Explore FMI!
Book a free demo
The global market holds around 28.5% share of the overall global painkillers market with a value of around USD 67.7 Billion, in 2022.
The increasing prevalence of chronic pain conditions, such as arthritis, cancer pain, and lower back pain, is one of the primary drivers of the pain therapeutic injectables market. These conditions require long-term pain management, which often includes the use of injectable pain medications. Due to the rise in chronic diseases, the market for pain therapeutic injectables has exhibited a consistent increase.
Apart from this, the market is anticipated to expand in the coming years because of the rising number of surgeries performed worldwide. This eventually demands post-operative pain management. Moreover, technological developments have led to improvements in drug delivery systems which ensures more accurate and effective administration of injectable drugs.
As the importance of pain management becomes more widely recognized, patients are seeking out effective pain relief options that can improve their quality of life. Pain therapeutic injectables are one such option that can provide rapid and effective relief from pain.
Owing to the above-mentioned factors, the global market is expected to grow at a prominent pace, and reach a valuation of around USD 30.9 billion in the year 2033.
There are numerous potentials for innovation and expansion in the market for companies dealing in pain therapeutic injectables. The market is being driven by the rising demand for minimally invasive procedures worldwide.
Minimally invasive procedures, such as injections, are becoming increasingly popular among patients due to their ability to reduce pain and discomfort while minimizing the risk of complications. This is driving the demand for pain therapeutic injectables, which can provide effective pain relief with minimal invasiveness.
The development of this market is anticipated to be aided by a number of new technologies and therapies. Due to their efficiency and patient convenience, injectable pain treatments are anticipated to see increased use.
As the global population ages, the prevalence of chronic pain conditions is expected to increase, which will drive demand for pain therapeutic injectables. The geriatric population is particularly susceptible to chronic pain, making them a key demographic for the pain therapeutic injectables market.
The market is constrained by a number of factors, including expensive injectable drug costs, adverse effects from prolonged use of opioids, and the possibility of drug abuse and addiction. Pain therapeutic injectables can be expensive, which can limit access for some patients. This is particularly true for those who do not have adequate health insurance coverage or who are underinsured.
The regulatory environment is also posing difficulties for the market, particularly when it comes to confirming the efficacy and safety of new injectable treatments before they can be released. The development and approval of new pain medications can be a lengthy and expensive process due to the strict regulatory requirements in many countries. This can limit the number of new products entering the market and slow down innovation.
The USA dominates the global region with a total market share of around 39.1% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
The market for pain therapeutic injectables in the USA is expanding due to a number of factors. One of the contributing aspects is the increasing prevalence of chronic pain. Chronic pain is a major healthcare issue in the United States, affecting millions of people each year. This has led to a growing demand for pain management therapies, including pain therapeutic injectables.
Other than this, an increase in awareness and education regarding the advantages of injectable painkillers such as their quicker onset of action and more accurate dosing, among medical professionals and patients, is driving the market in this region. In USA, the growth of the market is also fueled by the creation of novel and sophisticated injectable medications as well as the increased availability of enhanced delivery methods. These advancements are driving growth in the market by providing better treatment options for patients.
Japan contributed around USD 1.1 Billion revenue to the global pain therapeutic injectables market in 2022. The prevalence of chronic pain conditions is increasing in Japan, including osteoarthritis, cancer pain, and lower back pain.
This has led to a growing demand for pain therapeutic injectables. Additionally, as older people are more likely to have chronic pain, Japan's aging population is fueling the demand for pain management therapies, including pain therapeutic injectables.
The development of this market has also been aided by technological developments and the accessibility of new painkillers and treatments in Japan. The demand for pain treatment injectables in Japan has also been significantly influenced by patients' and healthcare professionals' growing knowledge regarding the importance of effective pain management.
Germany held a market share of 25.6% in the Western Europe pain therapeutic injectables market in 2022.
The market is expanding in Germany due to the growing popularity of minimally invasive procedures for pain management, which frequently involves the use of injectable medications.
Other than this, the demand for pain treatment injectables in the nation is also being fueled by the growing importance of at-home healthcare and self-administration of injectables. Overall, it is anticipated that these factors will continue to fuel the market for pain therapeutic injectables in Germany in the coming years.
Opioids by drug class segment held 53.4% share in the global market in 2022. Opioids are still frequently used to control pain, especially in situations where there is significant acute pain or chronic pain that does not respond to other forms of treatment. In recent years, although there has been a shift towards the use of non-opioid options for pain management, opioids still have a place in some circumstances.
Overall, opioids play a substantial role in the market of therapeutic injectables for treating pain, but their usage needs to be carefully regulated and balanced with other therapies.
Prescription drugs by product segment contributed around USD 11.3 Billion in the global market in 2022. Since they are frequently used to manage pain in individuals who require more intense therapy, prescription medications play a key role in the market of therapeutic injectables for treating pain.
The market for pain therapeutic injectables also has a prescription medicine sector that is significant because it offers healthcare professionals a variety of treatment alternatives to fulfill the various demands of their patients.
Surgical pain by indication segment held more than one-third revenue share in the global market in 2022. Injectable painkillers are in high demand because of the increasing prevalence of surgical pain conditions.
As a result of tissue damage and inflammation, patients who have undergone surgery, are most likely to experience pain so, pain treatment is a crucial component of post-operative care. Since pain therapeutic injectables can offer more immediate and intense pain relief than oral drugs, these are often utilized to alleviate the discomfort due to the pain.
Retail pharmacies is the leading segment with over 27.0% revenue share in 2022 globally. When it comes to distribution channel, retail pharmacies are considered a place which is quite accessible to patients in order to buy these kinds of injectable drugs. Therefore, retail pharmacies play a significant role in this market. Retail pharmacies typically stock a wide range of medications, including prescription drugs, over-the-counter medications, and other healthcare products. This makes it easy for patients to find the medications they need without having to visit multiple locations.
Key differentiating tactics used by producers of pain therapeutic injectables include an increase in product releases and regulatory body approval, growth into other regions, and marketing approvals in other locations. The dynamics of the market have changed as a result of increasing awareness.
Similarly, recent developments related to companies manufacturing pain therapeutic injectables have been tracked by the team at Future Market Insights. These are available in the full report.
| Attribute | Details |
|---|---|
| Historical Data Available for | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; East Asia; South Asia & Pacific; Western Europe; Eastern Europe; Central Asia; Russia & Belarus; Balkan & Baltic Countries; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Italy, BENELUX, Nordic Countries, United Kingdom, Poland, Hungary, Romania, Czech Republic, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, Australia & New Zealand, Japan, China, South Korea, GCC Countries, Kingdom of Saudi Arabia, Türkiye, Northern Africa, South Africa, and Israel |
| Key Market Segments Covered | Drug Class, Product, Indication, Distribution Channel and Region |
| Key Companies Profiled | AbbVie Inc. (Allergan plc); Bristol Myers Squibb Co.; Sanofi S.A.; Boehringer Ingelheim International GmbH; Pfizer Inc.; Zydus Lifesciences Ltd. (Cadila Pharmaceuticals); GSK plc.; Abbott Laboratories, Inc.; Novartis AG; Johnson & Johnson (Janssen Pharmaceuticals, Inc.); Sun Pharmaceutical Industries Ltd.; Teva Pharmaceuticals Ltd.; Mallinckrodt Pharmaceuticals; Endo Pharmaceuticals Inc.; Bayer AG; F. Hoffmann-La Roche Ltd.; Procter & Gamble; AstraZeneca; Cardinal Health; Perrigo Company Plc.; Bausch Health Companies Inc.; Viatris; Amneal Pharmaceuticals; Purdue Pharmaceuticals L.P. |
| Pricing | Available upon Request |
The United States, Japan, and China dominate the global pain therapeutic injectables market.
The pain therapeutic injectables market is forecast to register a CAGR of 4.5% through 2033.
The overall global painkillers market has a value of around USD 19.3 Billion in 2022.
Technological advancement disrupts the current market trends, such as the development of new pain medications and delivery methods.
The global market size of pain therapeutic injectables is to reach USD 30.9 Billion by 2033.
Pain Therapeutic Injectables Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
